News – Page 14 – Alligator Bioscience

2022-04-22

Invitation to the Presentation of Alligator Bioscience´s Interim Report January – March 2022 on April 27, 2022

LUND (Sweden) – April 22, 2022 – Alligator Bioscience will host a conference call (in English) for investors, analysts and media on Wednesda ...

2022-04-05

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2022-04-01

Lund, Sweden, April 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for th ...

2022-03-31

Regulatory

During the month of March, the number of shares and votes in Alligator Bioscience AB have increased due to directed issue and repurchase of ...

2022-03-23

Lund, Sweden, March 23, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical P ...

2022-03-22

Regulatory

Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of directors of Alligator Bioscience AB (”Alli ...

2022-03-22

Regulatory

Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2021 has been publi ...

2022-03-11

Regulatory

REGULATORY 11 March 2022 Ahead of the Annual General Meeting in Alligator Bioscience AB on May 5, 2022, the Nomination Committee announces i ...

2022-02-112022-05-17

Regulatory

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...